Stoke's Q2 2026 Update: Faster Dravet Readout Cuts Waiting Time, but the Stock Still Needs Proof

Phase 3 timing improved, but efficacy proof is still the main catalyst

Stoke's latest update improves the timeline, but it does not settle the bigger question. Earlier guidance pointed to Q2 2026 enrollment and mid-2027 readout. The current update reflects 162 patients enrolled and Q3 2027 readout. In other words, trial execution looks stronger, but the key Phase 3 efficacy readout is still ahead.

Why the Dravet program still matters

Dravet syndrome is a severe pediatric epilepsy, so the therapeutic bar is high. Stoke has positioned zorevunersen as a potential disease-modifying treatment rather than a symptom-control-only option. That keeps the program commercially interesting even while the definitive dataset is still pending.

Execution versus evidence

The stronger execution is clear enough: 162 patients enrolled suggests site engagement and trial execution are moving forward. But for investors, schedule progress is not the same as efficacy confirmation. The next decisive milestone is still the Phase 3 readout.

A more realistic January watchpoint

At the company's January J.P. Morgan presentation, investors should focus less on calendar language and more on whether management can connect operational progress to a more credible path to approval and clinical differentiation.

The asset still needs to pass the efficacy and regulatory tests

Timeline progress reduces one source of friction, but the core debate is still about the drug itself. The question is not whether the trial is moving faster. It is whether zorevunersen shows a signal strong enough to matter in Dravet syndrome.

What the current evidence supports

The strongest current support comes from longer-term, open-label data. Stoke has described the 3-year zorevunersen OLE data as showing continuing and durable reductions in seizures, along with improvements in cognition and behavior. That is encouraging, but open-label data still fall short of definitive proof.

Why EMPEROR and FDA feedback still matter more

The Q3 2027 EMPEROR readout remains the cleaner test of whether the early signal holds up without open-label bias. So does regulatory feedback.

Stoke has a pre-NDA meeting with the FDA scheduled for H2 2026, and it plans to initiate rolling U.S. NDA submission in Q1 2027. Those are important planning steps, but they are not efficacy data. They are also the points at which the FDA is likely to scrutinize the overall evidence package. Earlier this cycle, the agency requested additional information, and those discussions were still ongoing.

Other milestones on the way

Stoke also reported that the Phase 1 OSPREY study of STK-002 has dosing complete in sentinel cohort; dose escalation continuing and initial data anticipated in H1 2027. That adds breadth to the pipeline, but it remains secondary to the zorevunersen program for now.

For the near term, the key message is simple: better timing helps investor patience, but it does not replace the need for cleaner efficacy and regulatory confirmation.

Cash runway extends the timeline, but it does not remove the need for proof

Stoke now has $420 million in cash, cash equivalents and marketable securities, which the company says is enough to fund operations through potential U.S. commercialization of zorevunersen in early 2028. That materially reduces near-term financing pressure.

With financing less likely to dominate the story, attention can shift back to the asset. The next important checkpoints are the pre-NDA meeting in H2 2026, the planned rolling NDA submission in Q1 2027, and the Phase 3 EMPEROR readout in Q3 2027. For investors, that distinction matters: the cash buys time, not certainty.